Maha Sajjad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maha Sajjad has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Abdelrhman H. Mohamed
Faculty of Medicine, Luxor University, Luxor, Egypt
1 shared publication - Abdul Samad
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Ahmed Atef Mohamed
Faculty of Medicine, Helwan University, Cairo, Egypt
1 shared publication - Ahmed Khairy
Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication Aizaz Ali
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
1 shared publication- Alaa Eldeeb
Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication
Latest Publications
- Open Access
- 18 July 2026
- Published by Springer Nature in Archives of Public Health
- Vol. 84 (1) , 164
Ischemic heart disease mortality with documented tobacco use in the United States, 1999–2023: a nationwide population-based analysis
Background: Tobacco use is a major risk factor for ischemic heart disease (IHD), substantially increasing the likelihood of myocardial infarction, stroke, and premature mortality. This study examined U.S. trends in IHD mortality with documented tobacco use disorder from 1999 to 2023. Methods: CDC mortality data for adults aged ≥ 25 years with IHD (ICD-10 codes: I20–I25) and documented tobacco use (ICD-10 code: F17) listed as contributing causes of death were analyzed. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC). Results: From 1999 to 2023, 1,497,919 deaths were reported. The AAMR rose from 3.90 to 32.37 (AAPC: 10.71; p < 0.01). Males had a higher AAMR (39.68; AAPC: 10.72) than females (14.05; AAPC: 10.77). Non-Hispanic (NH) Whites had the highest AAMR (26.86), followed by American Indians (25.43), NH Blacks (19.77), and Hispanics (10.38). The Midwest had the highest regional AAMR (32.96). Most deaths occurred in inpatient facilities (27.9%). Adults aged ≥ 65 years had the highest mortality rate (CMR: 92.16). Rural areas exceeded urban (35.73 vs. 22.95). Conclusion: IHD mortality with documented tobacco use has risen sharply, disproportionately affecting older adults, males, rural areas, the Midwest, and NH Whites.
- 18 July 2026
- Published by Springer Nature in Archives of Public Health
- Vol. 84 (1) , 164
Open AccessIschemic heart disease mortality with documented tobacco use in the United States, 1999–2023: a nationwide population-based analysis
Background: Tobacco use is a major risk factor for ischemic heart disease (IHD), substantially increasing the likelihood of myocardial infarction, stroke, and premature mortality. This study examined U.S. trends in IHD mortality with documented tobacco use disorder from 1999 to 2023. Methods: CDC mortality data for adults aged ≥ 25 years with IHD (ICD-10 codes: I20–I25) and documented tobacco use (ICD-10 code: F17) listed as contributing causes of death were analyzed. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC). Results: From 1999 to 2023, 1,497,919 deaths were reported. The AAMR rose from 3.90 to 32.37 (AAPC: 10.71; p < 0.01). Males had a higher AAMR (39.68; AAPC: 10.72) than females (14.05; AAPC: 10.77). Non-Hispanic (NH) Whites had the highest AAMR (26.86), followed by American Indians (25.43), NH Blacks (19.77), and Hispanics (10.38). The Midwest had the highest regional AAMR (32.96). Most deaths occurred in inpatient facilities (27.9%). Adults aged ≥ 65 years had the highest mortality rate (CMR: 92.16). Rural areas exceeded urban (35.73 vs. 22.95). Conclusion: IHD mortality with documented tobacco use has risen sharply, disproportionately affecting older adults, males, rural areas, the Midwest, and NH Whites.
- 12 January 2026
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 136 (5) , 629-641
Evolving trends and disparities in malnutrition-linked stroke mortality in the United States: insights from CDC WONDER data
Stroke and malnutrition remain significant contributors to preventable mortality in the United States. Stroke is a leading cause of death and disability, while malnutrition, often underrecognized, exacerbates neurological and systemic vulnerability. Characterizing long-term national and subgroup-specific mortality patterns is critical for guiding public health interventions. Mortality data for stroke and malnutrition were analyzed from 1999 to 2023 using the Centers for Disease Control and Prevention's Wide Ranging Online Data for Epidemiologic Research (CDC WONDER) database. Age-adjusted mortality rates (AAMR) per 1,000,000 population were calculated and stratified by sex, race/ethnicity, census region, state and urbanization status. Joinpoint regression estimated average annual percent change (AAPC) with 95% confidence intervals (CIs). From 1999 to 2023, 44,368 deaths were attributed to malnutrition and stroke. The overall AAMR rose from 12.11 in 1999 to 14.75 in 2023, with an overall AAPC of 0.88% (95% CI: -0.14 to 1.91). Males had higher AAMRs than females. By race, Non Hispanic (NH) Black experienced the greatest AAMRs, whereas NH Asian had the lowest rates. Regionally, the South showed the highest rate, whereas Northeast had the lowest. Nonmetropolitan areas exceeded metropolitan areas. At the state level, the highest rates were observed in South Dakota and Arkansas, while Massachusetts recorded the lowest rates. From 1999 to 2023, combined mortality from stroke and malnutrition increased modestly nationwide, with enduring disparities across demographics and geography. The highest burdens fell on NH Black individuals, people living in the South and nonmetropolitan areas, and certain central states. These findings highlight the need for region-specific prevention and better access to nutritional and neurological care.
- 12 January 2026
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 136 (5) , 629-641
Evolving trends and disparities in malnutrition-linked stroke mortality in the United States: insights from CDC WONDER data
Stroke and malnutrition remain significant contributors to preventable mortality in the United States. Stroke is a leading cause of death and disability, while malnutrition, often underrecognized, exacerbates neurological and systemic vulnerability. Characterizing long-term national and subgroup-specific mortality patterns is critical for guiding public health interventions. Mortality data for stroke and malnutrition were analyzed from 1999 to 2023 using the Centers for Disease Control and Prevention's Wide Ranging Online Data for Epidemiologic Research (CDC WONDER) database. Age-adjusted mortality rates (AAMR) per 1,000,000 population were calculated and stratified by sex, race/ethnicity, census region, state and urbanization status. Joinpoint regression estimated average annual percent change (AAPC) with 95% confidence intervals (CIs). From 1999 to 2023, 44,368 deaths were attributed to malnutrition and stroke. The overall AAMR rose from 12.11 in 1999 to 14.75 in 2023, with an overall AAPC of 0.88% (95% CI: -0.14 to 1.91). Males had higher AAMRs than females. By race, Non Hispanic (NH) Black experienced the greatest AAMRs, whereas NH Asian had the lowest rates. Regionally, the South showed the highest rate, whereas Northeast had the lowest. Nonmetropolitan areas exceeded metropolitan areas. At the state level, the highest rates were observed in South Dakota and Arkansas, while Massachusetts recorded the lowest rates. From 1999 to 2023, combined mortality from stroke and malnutrition increased modestly nationwide, with enduring disparities across demographics and geography. The highest burdens fell on NH Black individuals, people living in the South and nonmetropolitan areas, and certain central states. These findings highlight the need for region-specific prevention and better access to nutritional and neurological care.
- Open Access
- 12 November 2025
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 19
Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials
Background: Hereditary transthyretin amyloidosis (hATTR) is caused by mutations in the transthyretin (TTR) gene, which lead to the aggregation of misfolded TTR protein and amyloid accumulation in the peripheral nerves, heart, and gastrointestinal tract. Recently, RNA therapeutics, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have been approved for treating patients with hATTR. Objectives: To assess the neurological efficacy and safety of RNA therapeutics in hATTR patients. Design: Systematic review and meta-analysis. Data sources and methods: A systematic literature search was conducted on PubMed, Cochrane, and ClinicalTrials.gov from inception to August 14, 2024. Outcomes included changes from baseline in the Norfolk Quality of Life–Diabetic Neuropathy (Norfolk QOL-DN) score and the modified Neuropathy Impairment Score +7 (mNIS + 7), modified body mass index (mBMI), adverse effects, serious adverse events, and all-cause mortality. Results: Our study included four RCTs with 842 patients (568 in the RNA therapeutics group and 274 in the placebo group). RNA therapeutics significantly improved Norfolk QoL-DN (mean difference (MD), −18.79; 95% CI, −22.32 to −15.25; p < 0.00001; I 2 = 28%) and mNIS + 7 scores (MD, −26.90; 95% CI, −31.67 to −22.13; p < 0.00001; I 2 = 61%), with significant preservation of mBMI (MD, 114.98; 95% CI, 90.64–139.32; p < 0.00001; I 2 = 59%) compared to placebo. There were no significant differences between the two groups regarding the risk of adverse effects (risk ratio (RR), 0.89; 95% CI, 0.69–1.15; p = 0.36; I 2 = 34%), serious adverse effects (RR, 0.70; 95% CI, 0.31–1.58; p = 0.39; I 2 = 20%), and all-cause mortality (RR, 0.70; 95% CI, 0.31 to 1.58; p = 0.39; I 2 = 20%). Conclusion: RNA therapeutics are effective and well-tolerated in patients with hATTR, significantly improving quality of life and the progression of neurological impairment. siRNAs demonstrate better outcomes compared to ASOs. Trial registration: PROSPERO (CRD42024568346).
- 12 November 2025
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 19
Open AccessNeurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials
Background: Hereditary transthyretin amyloidosis (hATTR) is caused by mutations in the transthyretin (TTR) gene, which lead to the aggregation of misfolded TTR protein and amyloid accumulation in the peripheral nerves, heart, and gastrointestinal tract. Recently, RNA therapeutics, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have been approved for treating patients with hATTR. Objectives: To assess the neurological efficacy and safety of RNA therapeutics in hATTR patients. Design: Systematic review and meta-analysis. Data sources and methods: A systematic literature search was conducted on PubMed, Cochrane, and ClinicalTrials.gov from inception to August 14, 2024. Outcomes included changes from baseline in the Norfolk Quality of Life–Diabetic Neuropathy (Norfolk QOL-DN) score and the modified Neuropathy Impairment Score +7 (mNIS + 7), modified body mass index (mBMI), adverse effects, serious adverse events, and all-cause mortality. Results: Our study included four RCTs with 842 patients (568 in the RNA therapeutics group and 274 in the placebo group). RNA therapeutics significantly improved Norfolk QoL-DN (mean difference (MD), −18.79; 95% CI, −22.32 to −15.25; p < 0.00001; I 2 = 28%) and mNIS + 7 scores (MD, −26.90; 95% CI, −31.67 to −22.13; p < 0.00001; I 2 = 61%), with significant preservation of mBMI (MD, 114.98; 95% CI, 90.64–139.32; p < 0.00001; I 2 = 59%) compared to placebo. There were no significant differences between the two groups regarding the risk of adverse effects (risk ratio (RR), 0.89; 95% CI, 0.69–1.15; p = 0.36; I 2 = 34%), serious adverse effects (RR, 0.70; 95% CI, 0.31–1.58; p = 0.39; I 2 = 20%), and all-cause mortality (RR, 0.70; 95% CI, 0.31 to 1.58; p = 0.39; I 2 = 20%). Conclusion: RNA therapeutics are effective and well-tolerated in patients with hATTR, significantly improving quality of life and the progression of neurological impairment. siRNAs demonstrate better outcomes compared to ASOs. Trial registration: PROSPERO (CRD42024568346).